UBM — Ulisse Biomed Spa Income Statement
0.000.00%
- €22.13m
- €19.83m
- €0.07m
Annual income statement for Ulisse Biomed Spa, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.011 | 0.429 | 0.277 | 0.138 | 0.066 |
Cost of Revenue | |||||
Gross Profit | -0.697 | 0.2 | -0.269 | -0.895 | -1.55 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.13 | 0.204 | 0.88 | 1.44 | 2.54 |
Operating Profit | -1.12 | 0.224 | -0.603 | -1.31 | -2.47 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.12 | 0.224 | -0.604 | -1.31 | -2.47 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.1 | 0.222 | -0.604 | -1.31 | -2.47 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.1 | 0.222 | -0.604 | -1.31 | -2.47 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.1 | 0.222 | -0.604 | -1.31 | -2.47 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.136 | 0.028 | -0.075 | -0.162 | -0.298 |